articleTop 10% cited

Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies

Clinical Cancer Research · 2004 · Vol. 10(11) · pp. 3708–3716

Tae‐You Kim✉(Seoul National University)Dong-Wan KimJae‐Yong Chung(Seoul National University)Sang Goo Shin(Seoul National University)Sungchul KimDae Seog HeoNoe Kyeong KimYung‐Jue Bang

View via DOI Publisher page

Abstract

The main dose-limiting toxicities were neuropathy, myalgia, and neutropenia, and the recommended dosage for a phase II study is 300 mg/m(2). Genexol-PM is believed to be superior to conventional paclitaxel in terms of the obviation of premedication and the delivery of higher paclitaxel doses without additional toxicity.

Cancer Treatment and Pharmacology Nanoparticle-Based Drug Delivery Multiple Myeloma Research and TreatmentsPharmacokineticsmyalgiaMedicinePaclitaxelTaxaneNeutropeniaPharmacologyToxicityPremedicationRefractory (planetary science)

MeSH terms

AdultAntineoplastic AgentsAntineoplastic Agents, PhytogenicDose-Response Relationship, DrugFemaleHumansMaleMicellesMiddle AgedNeoplasmsPolyethylene GlycolsPolymersTime FactorsPaclitaxelArea Under Curve

Citations

798

FWCI

8.44

field-weighted impact

References

Percentile

98%

vs. same field & year

Citations per year

Cited by

Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy